Old news, but I was very surprised when I read that. The FDA usually looks askance at treatments that provide a progression-free survival advantage but no overall survival advantage. I was thinking Array would get ODD for thyroid cancer with all the compassionate-use requests I saw. Hopefully, ODD for thyroid cancer will happen soon, but ODD for uveal melanoma is nice, too.
VentiRx is under the radar but recently getting orphan drug designation from European Commission for ARRY's motolimod in combination with pegylated liposomal doxorubicin as an ovarian cancer treatment is nothing to sneeze at. The combo received fast track designation from the FDA for the same disease last September, too. Array had the option to buy a 50% ownership position in any drug developed under this agreement, but Celgene liked this drug so much that they decided they wanted in on it, too, and paid $35 million upfront and agreed to help pay for the clinical trials.
Oncothyreon's stock had a nice runup today, but with a roughly $150 million market cap, I think it's ridiculously cheap considering PBYI has a $6 billion market cap. ONTY's HER2+ drug is only in Phase I and PBYI's neratinib is at the NDA stage, but patients on ONT-380 have much fewer adverse events because the drug targets HER2 very specifically.
It's been about a year since Array announced a collaborations with Biogen and almost two years since the Celgene partnership was formed. Would be nice if Array provided an update for either one.
You have to be impressed with a company that licenses similar drugs targeting the same kinase to different big pharma companies not once (selumetinib and binimetinib) but twice (GDC-0575 and LY2606368).
Obviously, there's way more going on than that with ARRY, and it's a buy-it-and-forget-it stock for me. They have some very smart people working for them who have discovered some amazing drugs targeting a wide variety of diseases. Which is why I wasn't crazy about those layoffs announced back in August of 2013. Why mess with something that's working so well?
And for those morons braying on about a possible buyout: you're the kind of geniuses who would slice open the goose that laid the golden eggs, right?
You're wrong. Wells Fargo has covered ARRY conference calls since at least October 31st of 2013.
To be technical, Duke genetically modified the polio virus and it was that that was injected in the patients, not the vaccine. ARRY isn't targeting GBM, but they have filanesib for multiple myeloma and possible competitiors are using the measles virus on MM with mixed results so far.
In August of 2013, I was very disappointed when I saw this news (google Array cuts 20 percent jobs; says Amgen ends partnership). So they let 20% of their workforce go less than 2 years ago and now they're bringing some of those jobs back. Doesn't look stupid at all. I'm an ARRY bull, but I've been coming around on agreeing with the folks who want Ron gone.
Thanks Burnaka, but I don't hear very well and was hoping to see the actual slides. I'll be emailing Ms. Haugeto!
I must be missing something, I can't find it. Can you tell me where on their site the presentation is? Thanks in advance.
I see three hits for MEK162, including one where both MEK162 and selumetinib are mentioned (3330 4818 and 919). Selumetinib alone in 4490. ARRY-614 has one (4628).
To keep people from wasting their time - especially any newbies, any posts from buyoutmoney175/andswhisper/discoverymole/peixmole/saicinthemoney/republicans_against_bush/nk499/yunsu5040 are from the same mentally-deficient loser who thinks it's clever to refer to Ron Squarer as "Square Ron" and bash him for not buying shares of ARRY or for talking a good game and not delivering a higher stock price. The same idiot posts the "MARK THIS POST, BUYOUT AT $8.88!!" or "hearing rumors of a buyout" #$%$ on a weekly basis.
Dude, you haven't gotten nibbles on the buyout #$%$ in months, are you that slow a learner? The level of discourse here is low because you constantly #$%$ all over the board. Find some Justin Bieber board to ruin and leave us adults in peace.
Don't get me wrong, I'm an underwater long, but if the treatment were that effective, why don't they have a big pharma company pairing their checkpoint inhibitor modulator as part of their Phase IIIs? I was very unhappy that they teased in their CCs that they were talking to the big boys about pairing their treatment with, say, an anti-PD-L1 and didn't follow through. I'm seeing that as a vote of no-confidence from smart money folks.
If you haven't already, join the moderated CURIS Google Group. Erivedge sales are picking up, but the combo efforts have failed left and right and management has mishandled their other drugs. I think there are a lot of better places to put your money, but good luck to ya.
Yeah, him. Treated the company as his personal piggy bank, screwed up the dosing for 907, wasted time trying Debio 0932 as an IV drug and read up on the sham businesses of the one board member.
Don't sleep on VTX-2337, some interesting tweets from LSINW this weekend. I missed that Celgene partnered with VentiRX to help bring VTX-2337 to market, but I like the legitimacy and know-how that Celgene brings. Been hoping that VTX-2337 would be paired with a checkpoint inhibitor modulator because everything I'd read made it sound like they'd work great together and was happy to see that it's going to happen.
ARRY owns preferred equity in VentiRX and can get $56 million in milestone payments from this agreement, so it won't potentially be a huge source of revenue, but with all that ARRY has going on, it can be a part of a bunch of potential revenue sources that can add up.
Sentiment: Strong Buy
It's on the latest 10-Q: ARRY owns 19.9%, 3rd party valuation firm says the shares are worth $4.5 million. ARRY also owns preferred shares of VentiRX worth $1.5 million. Two of many reasons ARRY is a no-brainer investment.
Sentiment: Strong Buy
More like 40 Phase 2s. Ron has said there are 32 Phase 2s and above for Selumetinib, which makes 29 Phase 2s there and he's said there are 17 active Phase 1s and Phase 2s for Binimetinib. I count 16 at clinicaltrials and of those, 11 are Phase 2s.
Sentiment: Strong Buy